Member Info for ContrarianQuest

Sneller vs. Mills — Who’s Really the More Successful Backer for TRX?

There’s been a lot of talk about Sneller’s exit and what it means for Tissue Regenix (TRX). Let’s put things in perspective regarding him versus Christopher Mills and Harwood Capital.

Richard Sneller was the long-time main backer of TRX, holding around 15% through himself and related companies. He comes from a solid background, including years at Baillie Gifford focusing on emerging markets. He’s a respected investor but more of a traditional asset manager rather than an activist. His support was a steadying presence for TRX, but his recent sell-down likely reflects a loss of confidence or portfolio reshuffle—there’s no clear standout turnaround success linked to him or his holdings in TRX.

On the other side, we have Christopher Mills and Harwood Capital, who are known as true activist investors with a long, proven track record. Over 40+ years, Harwood’s North Atlantic Smaller Companies Trust has delivered about a 13% annualized return—a solid indication of consistent outperformance. Mills doesn’t just buy shares; he actively pushes companies for changes in strategy, governance, and performance to unlock value.

His recent move to increase Harwood’s stake in TRX from around 15% to over 22% signals that this is exactly the kind of turnaround play he believes in and wants to influence hands-on. Mills’ reputation is built on getting involved in special situations, driving real change, which contrasts with Sneller’s more passive style.

In summary:

Sneller is a seasoned, respected investor but lacks a clear activist or turnaround success record at TRX.

Mills represents a more successful, impactful investor type who is actively shaping TRX’s future with a consistent history of value creation in smaller UK companies.

If you’re looking at who brings more success and influence to the table for TRX’s turnaround, Mills and Harwood clearly have the edge.

While Sneller’s exit caused short-term market jitters, Harwood’s entry and the leadership changes suggest a credible turnaround is underway, reducing the risk of a negative outcome implied by the comment. This pattern of key shareholder transition is common in companies repositioning for recovery.

In summary, although Sneller’s selling created a reaction, the institutional vote of confidence combined with new leadership does not support a doom scenario. The company appears to be entering a new phase with better governance and execution focus, making a successful turnaround more likely.

The comment "Once Sneller starts selling TRX have a problem, he's been the main backer for years. You bulls crack on, it won't end well for you guys imo." captures a common bearish worry about Tissue Regenix (TRX) centered on Richard Sneller's exit as a major shareholder.

From public disclosures, Richard Sneller was indeed one of the long-term main backers holding positions through himself and associated entities (like Inthallo Ltd). His stake dropped below a major threshold in late September 2025, signaling a substantial sell-down.

This exit triggered some market anxiety as Sneller had been viewed as a key supporter providing stability and confidence to other investors. The fear is that if a major backer sells heavily, it might imply loss of faith or create selling pressure.

However, this concern is counterbalanced by:

Harwood Capital stepping in and increasing its stake from ~15% to over 22%, becoming the largest institutional investor with a clear activist value-investor profile supportive of a turnaround.

The company’s board openly acknowledging the need to improve, bringing in turnaround specialist Jay LeCoque to strengthen leadership and operational execution.

Institutional buying by Harwood suggests confidence that Sneller’s exit was not necessarily a sign of fundamental trouble, but possibly portfolio reshuffling or different investment priorities.

While Sneller’s exit introduces a short-term risk and a psychological blow, the replacement of his position by an engaged institutional investor with a strong track record arguably reduces overall shareholder risk. The company is transitioning from reliance on a retail/individual backing base to more stable, strategic institutional ownership.

In sum, Sneller selling was a catalyst for volatility and sentiment loss, but the strong Harwood entry and new leadership position TRX for a more credible turnaround path, countering the doom narrative that "it won’t end well."

So, while caution is warranted, the evidence points more to a changing guard than collapse — a typical phase during turnarounds where ownership shifts before potential recovery.The comment reflects a common concern among investors: Richard Sneller, a long-time major backer of Tissue Regenix (TRX), significantly reduced his stake below a key threshold in late September 2025. As Sneller had been seen as a stable, supportive shareholder for years, his sell-off raised worries about confidence in the company and triggered selling pressure.

However, this concern is mitigated by Harwood Capital increasing their stake from around 15% to over 22%, becoming the largest single institutional investor. Harwood’s move signals strong institutional confidence, as they are known for backing turnarounds in UK small caps. The company also appointed turnaround expert Jay LeCoque as Executive Chairman, and the board has openly acknowledged the need to improve performance.

Tissue Regenix (TRX) — The Real Deal Right Now

New Exec Chair Jay LeCoque is exactly the turnaround leader TRX needed, already pushing for sharper focus and fixes.

The board openly admits performance must improve and they’re fully committed to delivering this, especially in H2 2025.

Big milestones on the horizon: ISO 13485 certification, FDA approvals, and ramping up direct sales with 32+ new dCELL distributors.

Institutional backing just got stronger: Harwood Capital boosted their stake from ~15% to over 22%. That’s a huge vote of confidence and eases cash raise fears.

Yes, risks remain with execution and funding, but the market has already dumped the stock hard — current price (~10.5–11p) heavily discounts these.

Given all this info, the odds seem strongly in favour of a successful turnaround. A price rebound to 15p–25p in 12–24 months looks quite realistic.

DYOR, but I believe at this level with everything lined up, Tissue Regenix is a compelling investment opportunity.

Issues with my computer - I dug into the RNSs — turns out Sneller’s stake fell from ~15.1% to

I dug into the RNSs — turns out Sneller’s stake fell from ~15.1% to

I dug into the RNSs — turns out Sneller’s stake fell from ~15.1% to

“RNSs confirm the move: Harwood/Oryx lifted to 22.12% (15.79m shares) on 2 Oct, while Richard Sneller’s holding fell below a major threshold on 30 Sep. That suggests a large seller created the overhang and Harwood stepped in to buy — a strong institutional vote of confidence and it materially reduces immediate dilution/placement risk. DYOR.”

The “cash call soon” line doesn’t stack up with the facts:

Harwood just lifted to 22.1% (15.8m shares) — they wouldn’t buy 5m shares if a cheap placing was around the corner.

Cash was £1.1m at June 30 and they’ve got a £16m facility (£10.4m drawn, maturing 2028), which gives headroom.

Company is still adjusted EBITDA positive and guiding for H2 improvements — not the profile of a business in urgent need of cash.

No RNS about a raise, and AIM rules mean they’d have to announce if one was imminent.

Growth catalysts (ISO 13485, FDA certificates, OrthoPure approvals, 32 new dCELL distributors) are still ahead and could support revenues.

In short: there’s always some funding risk in small caps, but there’s no evidence for an emergency raise here. The recent sell-off was more about the 15% dump, and Harwood’s buying suggests they see this as a turnaround play, not a cash crisis.

“Big move just landed — Harwood have lifted their TRX stake from 15% to 22% (15.8m shares). That’s a serious vote of confidence from a respected fund who know turnarounds. The market’s been hammering TRX, but if the BOD keep sharpening focus as promised, sentiment could flip fast. Institutions are buying — always worth noting.”

TRX has been punished hard by the market — down from 20p to ~11p — but that feels like an overreaction. H1 sales slipped 6% and cash is tight, but debt is covered to 2028 and EBITDA still positive. The BOD openly admit results must improve and are sharpening focus, with turnaround pro Jay LeCoque now leading the charge. Big catalysts (ISO 13485, FDA approvals, direct dCELL sales network growth) are all in play.

Bullish take: If execution lands, this could be a serious recovery play — 20–30p near term, 60p+ longer term.

Balanced take: Growth is achievable with approvals + distribution, but dilution risk remains if cash burn doesn’t ease.

Cautious take: Sales are down, liquidity thin, and sentiment rough, so more volatility ahead.

At the end of the day, the market can flip on a dime — once it sees TRX executing, sentiment and share price could turn very quickly, and so could the market cap. High risk, high reward. DYOR.

This is my understanding so far shown below, happy to be corrected by more experienced posters .

Helium One Global Ltd's Investment Agreement from July 2025 is for a £10 million convertible advance. So far, conversion notices amounting to £4,375,000 have been received and converted into shares in three tranches:

£1,000,000 converted on 19 August 2025 at 0.5007p per share.

£1,725,000 converted on 29 August 2025 at 0.42p per share.

£1,650,000 converted on 24 September 2025 at 0.235p per share.

This means that £5,625,000 of the £10 million advance remains to be converted or repaid.

There is no publicly announced fixed schedule or predetermined conversion prices for the remaining amount in the agreement. The Investors may choose to convert any remaining outstanding amount at any time within 12 months of the drawdown (so by July 2026), with the conversion price calculated similarly—a discount to the market VWAP price over a defined period prior to conversion.

If the advance is not converted by the maturity date (12 months after drawdown), Helium One may repay it in cash, shares, or a combination. If an event of default occurs, repayment would be accelerated with interest.

In summary:

Approx. £5.6 million remains outstanding from the £10 million advance.

Investors can convert remaining advances into shares anytime before maturity (mid-2026).

Conversion prices will be discounted relative to the market price at conversion time.

No specific future conversion dates or prices have been disclosed yet.

This flexibility allows investors to decide when and how much to convert based on market and company progress

This is my understanding so far shown below, happy to be corrected by more experienced posters .

Helium One Global Ltd's Investment Agreement from July 2025 is for a £10 million convertible advance. So far, conversion notices amounting to £4,375,000 have been received and converted into shares in three tranches:

£1,000,000 converted on 19 August 2025 at 0.5007p per share.

£1,725,000 converted on 29 August 2025 at 0.42p per share.

£1,650,000 converted on 24 September 2025 at 0.235p per share.

This means that £5,625,000 of the £10 million advance remains to be converted or repaid.

There is no publicly announced fixed schedule or predetermined conversion prices for the remaining amount in the agreement. The Investors may choose to convert any remaining outstanding amount at any time within 12 months of the drawdown (so by July 2026), with the conversion price calculated similarly—a discount to the market VWAP price over a defined period prior to conversion.

If the advance is not converted by the maturity date (12 months after drawdown), Helium One may repay it in cash, shares, or a combination. If an event of default occurs, repayment would be accelerated with interest.

In summary:

Approx. £5.6 million remains outstanding from the £10 million advance.

Investors can convert remaining advances into shares anytime before maturity (mid-2026).

Conversion prices will be discounted relative to the market price at conversion time.

No specific future conversion dates or prices have been disclosed yet.

This flexibility allows investors to decide when and how much to convert based on market and company progress

Last trade recorded on todays log, trade 227 recorded as a sell, at 0.3276 - 15,000,000 timed at 08:13:30, someone wanted to offload after this morning RNS. They decided to hold that one back until after hours.

Its Friday so all in a weeks trading, ready for next week when I am pretty sure we will see a repeat of this week, DYOR

AIM stocks like HE1, the market often moves in cycles where a sharp price rise attracts momentum buyers and speculators, which creates liquidity and briefly drives prices up. Early buyers who entered at lower prices then take profits, selling into strength as price rallies, which increases supply and frequently triggers a reversal once demand is met or the next wave of buyers dries up.

This “pump and dump” or “buy-reverse-sell” cycle is common in microcaps with overhang risk and can be repeated multiple times, especially when dilution from CLNs or new raises is expected.

Here we go folks it a profit taking day for anyone who bought in at 0.27/0.28 take 10% and start again

Do I see a slight manipulation and P&D? only time will tell, place your bets

Orders waiting for 0.26p and 0.25p

LOTM-13 - great post, accurately describing the convertible loan note (CLN) conversion mechanism and its dilutive impact on Helium One's share price in 2025.

I totally agree, when the BOD have very little skin in the game, for me this tells me a lot.

If you want to see other AIM's where they have serious skin in the game and where it is a different story, look at Oriole Resources ORR. Now they have just completed their death spiral and have come out the other side, the board are engaging and approachable, and the company could be on the cusp of good times, but the point is the BOD and the Non Executive chair has serious skin invested, tells me all I need to know.